Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

MacKenzi Heaton

Nurse Practitioner Spokane, WA Nurse Practitioner

NPI 1811657034 CMS profile 11311024

6001 N Mayfair St, Spokane, WA 99208

Open in the dashboard

General payments

$11,520

411 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, MacKenzi Heaton of Spokane, WA is reported in the CMS Open Payments database as having received $11,520 across 411 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,221 30
2024 General $2,344 80
2023 General $4,047 166
2022 General $3,907 135

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • MacKenzi Heaton
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to MacKenzi Heaton were reported at $1,221. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year MacKenzi Heaton Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $3,907 $152 $48–$470 $149
2023 $4,047 $166 $54–$529 $160
2024 $2,344 $173 $55–$556 $164
2025 $1,221 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. E.R. Squibb & Sons, L.L.C. $832 34 payments
  2. Pfizer Inc. $643 47 payments
  3. Novartis Pharmaceuticals Corporation $602 34 payments
  4. Daiichi Sankyo Inc. $557 6 payments
  5. Janssen Biotech, Inc. $557 19 payments
  6. AstraZeneca Pharmaceuticals LP $554 13 payments
  7. Celgene Corporation $542 34 payments
  8. Lilly USA, LLC $389 12 payments
  9. Merck Sharp & Dohme Corporation $336 12 payments
  10. Genzyme Corporation $335 9 payments
  11. Other $6,173 191 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $10,710 400 payments
  2. Education $809 11 payments
Products named General payments · program years 2022–2025
  1. SARCLISA $380 8 payments
  2. IMBRUVICA $376 6 payments
  3. REBLOZYL $346 22 payments
  4. IBRANCE $346 22 payments
  5. KEYTRUDA $336 12 payments
  6. OPDIVO $285 9 payments
  7. KISQALI $277 15 payments
  8. CYRAMZA $277 7 payments
  9. SCEMBLIX $269 16 payments
  10. TUKYSA $268 12 payments
  11. Other $9,463 398 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

16

Median for Nurse Practitioner: 389

Drug cost

$128

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prochlorperazine Maleate Generic 16 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$16,649

Medicare's payments for the services billed

Medicare patients

36

Average age 74

Services billed

856

17 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 58%
Arthritis 50%
Chronic kidney disease 36%
Osteoporosis 31%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SARCLISA
  • GENZYME CORPORATION $159
  • SANOFI-AVENTIS U.S. LLC $91
$250 — —
OJJAARA
  • GlaxoSmithKline, LLC. $161
$161 — —
SCEMBLIX
  • Novartis Pharmaceuticals Corporation $153
$153 — —
CABOMETYX
  • Exelixis Inc. $125
$125 — —
BRUKINSA
  • BeiGene USA, Inc. $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

411 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record